Orally Disintegrating Tablet Industry Expected to Reach $22.53 Billion by 2029 at 8.6% CAGR

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

Orally Disintegrating Tablet Market Value Projection: How Much Will the Market Size by 2025?
The market size for orally disintegrating tablets has seen significant growth in recent times. It is projected to increase from $14.88 billion in 2024 to $16.20 billion in 2025, with a compound annual growth rate (CAGR) of 8.8%. Factors that have contributed to this growth in the past include the increasing number of elderly and pediatric populations, a higher prevalence of central nervous system disorders, heightened demand for easy drug administration, rising occurrences of dysphagia, and increased utilization of outpatient care.

What Will Be the Market Growth Forecat for Orally Disintegrating Tablet in 2029?
The market for orally disintegrating tablets is projected to significantly expand in the coming years, ballooning to $22.53 billion by 2029 with a compound annual growth rate (CAGR) of 8.6%. This prospective growth during the forecast period is linked to several factors including the escalating chronic disease prevalence, growing inclination towards self-medication, increased adoption of telemedicine and e-pharmacies, heightened emphasis on personalized medicine, surging demand for vegan and allergen-free formulations, and a burgeoning senior population. The forecast period will also see several advancements such as multi-drug orally disintegrating tablet development, integration with digital health platforms, innovation in product packaging for increased stability and transportability, taste-masking technologies, and progression in formulation technology.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

What Are the Core Competitive Drivers in the Orally Disintegrating Tablet Industry?
The surge in neurological disorder cases is anticipated to spur the expansion of the orally disintegrating tablet market. Neurological disorders, which disrupt the nervous system's normal processes, including the brain and peripheral nerves, are becoming increasingly prevalent mainly due to extended life spans. With aging, conditions such as Alzheimer's and Parkinson's become more frequent, resulting in an overall uptick in instances. Orally disintegrating tablets provide a solution for neurological disorders by facilitating swift and simple medication administration, especially for those with swallowing difficulties (dysphagia) and cognitive obstacles. This not only enhances treatment compliance but also ensures punctual dosing, thereby boosting the therapy's overall effectiveness. Information from the Alzheimer's Association, a US nonprofit voluntary health organization, reveals that in March 2023, roughly 6.7 million Americans aged 65 or over live with Alzheimer's dementia, a figure predicted to double to 13.8 million by 2060. Consequently, the escalating prevalence of neurological disorders is fostering the growth of the orally disintegrating tablet market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

Which Orally Disintegrating Tablet Market Segment Is Projected to See the Fastest Growth?
The orally disintegrating tablet market covered in this report is segmented -

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Opening New Opportunities in the Orally Disintegrating Tablet Market?
Leading businesses in the orally disintegrating tablet market are directing their efforts towards innovative drug formulations, notably those centered around the patient, to boost adherence to medication and better patient results. This patient-focused approach to medication involves creating and administering drugs in ways that are more convenient and comfortable for patients, leading to an enhanced treatment experience and greater compliance. Taking the case of Viatris Inc., a healthcare firm situated in the U.S., they rolled out Gen-Clozapine orally disintegrating tablets (ODT) in May 2025, in Canada, introducing a fresh therapeutic possibility for those coping with treatment-resistant schizophrenia. This product brings a number of exclusive attributes to the table, hence, making it an important addition to the management of treatment-resistant schizophrenia in the Canadian health system. Being the inaugural clozapine orally disintegrating tablet (ODT) on the Canadian market, it manages to be a patient-friendly choice that dissolves rapidly in the mouth sans water, providing a solution for those who have difficulty swallowing or with compliance-related hurdles. Available in various potencies (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), it presents the opportunity for detailed and flexible dose titration in accordance with individual patient needs. Utilizing clozapine, which remains the sole antipsychotic ratified for treatment-resistant schizophrenia, the ODT formulation abets compliance with affirmed treatment protocols.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Who Are the Leaders in the Orally Disintegrating Tablet Market?
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc.

Which Regional Orally Disintegrating Tablet Markets Offer the Greatest Growth Potential?
North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.